Role of Second-Line Systemic Treatment Post-Docetaxel in Metastatic Castrate Resistant Prostate Cancer- Current Strategies and Future Directions

Jawaher      Ansari; Syed      A Hussain; Abdulla      Alhasso; Rana      Mahmood; Asif      Ansari; John      Glaholm

Abstract

Treatment of metastatic castrate resistant prostate cancer (mCRPC) after progression on docetaxel chemotherapy is a challenging clinical scenario with limited availability of treatment options. Re-treatment with docetaxel, either as monotherapy or in combination with other cytotoxics or targeted agents has shown durable responses. However, most docetaxel re-treatment studies have been either retrospective or early phase non-randomised studies which have not formally assessed Quality of life or survival gain with re-treatment. Despite limited evidence for efficacy of mitoxantrone in the second-line, it continues to remain widely used, largely due to lack of available suitable alternatives. Cabazitaxel in combination with prednisolone is the only chemotherapy to have shown a significant survival benefit and receive approval by the U.S. Food and Drug Administration for patients with mCRPC previously treated with a docetaxel-based regimen. Abiraterone acetate has recently demonstrated a significant improvement in survival when compared to placebo in patients with docetaxel-treated mCRPC. This review aims to summarize the current evidence and discuss future strategies for treatment of mCRPC patients following failure of docetaxel chemotherapy.

Keywords: Metastatic castrate resistant prostate cancer, post-docetaxel chemotherapy, metastatic prostate cancer, docetaxel resistant prostate cancer, abiraterone, cabazitaxel, Prostate Cancer, mCRPC, Docetaxel, Bevacizumab, Carboplatin, Estramustine, MITOXANTRONE CHEMOTHERAPY, Platinum-Based Chemotherapy